Eduardo Sotomayor, MD

Description

Dr. Sotomayor is the director of the newly established Cancer Institute at Tampa General Hospital. He is a pioneer in the field of cancer immunology and immunotherapy and an internationally renowned expert in lymphoma research and treatment. Prior to joining Tampa General, he was the director of the George Washington University Cancer Center with responsibility and authority over all aspects of cancer care and research at GW and affiliated health systems. He was also a professor of medicine in the division of hematology/oncology at George Washington University School of Medicine and Health Sciences. Dr. Sotomayor has returned to Tampa, where he previously had a highly productive 15-year tenure with Moffitt Cancer Center. He served as the Susan and John Sykes Endowed Chair of Hematologic Malignancies and chair of the department of malignant hematology. In addition, he was the scientific director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. He also guided future medical professionals as a professor in the University of South Florida College of Medicine’s departments of oncologic sciences, and pathology and cell biology. Fluent in English and Spanish, Dr. Sotomayor specializes in the treatment of lymphomas and leukemias. The accomplished physician-scientist’s ongoing research is directed toward cancer immunology and immunotherapy with special focus in developing novel immune-based approaches for the treatment of lymphomas and other hematologic malignancies. Considered as a world expert in mantle cell lymphoma (MCL), he has more than 140 publications including seminal discoveries published in top tier journals such as Nature Immunology, Nature Medicine, Blood, Proceedings of the National Academy of Sciences, Cancer Cell among others. He has been the recipient of several awards, including the recipient of the National Cancer Institute (NCI) CURE Lifetime Achievement award in 2017. Dr. Sotomayor is involved in several major medical societies and organizations and currently is a member of the Scientific Advisory Board, Lymphoma Research Foundation, member of the Executive Committee of the Mantle Cell Lymphoma Consortium and member of several committees of the American Association for Cancer Research (AACR). He has also served in committees at the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO) and the National Cancer Institute (NCI)